4.7 Article

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer

Yiqi Fan et al.

Summary: Triple-negative breast cancer (TNBC) is a unique subtype of breast cancer with high intrinsic heterogeneity and a distinct immune microenvironment. Understanding the TNBC microenvironment is crucial for the prognosis and treatment of this disease.

CANCER MANAGEMENT AND RESEARCH (2022)

Article Oncology

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity

Shinya Abe et al.

Summary: By physically disrupting the tumor microenvironment (TME) through mechanical high-intensity focused ultrasound (M-HIFU), the activation status of tumor-associated macrophages (TAMs) can be changed, leading to enhanced T-cell infiltration. When combined with anti-PD-L1 antibody, M-HIFU can mediate superior systemic antitumor immune responses and suppress distant tumor growth.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy

Melinda L. Telli et al.

Summary: This study demonstrates that Tavo treatment can enhance the CXCR3 gene expression within tumors, leading to improved antigen presentation, T-cell infiltration, and PD-1/PD-L1 expression, ultimately improving the therapeutic outcomes for patients with TNBC.

CLINICAL CANCER RESEARCH (2021)

Article Biotechnology & Applied Microbiology

Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles

Zeting Yuan et al.

Summary: Recent studies show that photodynamic therapy (PDT) can enhance the therapeutic effects of PD-L1 blockade in colorectal cancer (CRC) by inducing tumor cell death, stimulating immune response, and preventing tumor recurrence through upregulation of PD-L1 expression via the hypoxia-inducible factor 1a (HIF-1a) signaling pathway. This combination therapy using multifunctional nanoparticles loaded with photosensitized mTHPC (mTHPC@VeC/T-RGD NPs) shows promise in improving the response rate of anti-PD-L1 checkpoint blockade immunotherapies in CRC.

MOLECULAR THERAPY (2021)

Article Multidisciplinary Sciences

Inference and analysis of cell-cell communication using CellChat

Suoqin Jin et al.

Summary: By constructing an interaction database and developing the tool CellChat, the authors quantitatively inferred and analyzed cell-cell communication networks, revealing important signaling inputs and outputs between cells, and achieved classification of conserved and context-specific pathways.

NATURE COMMUNICATIONS (2021)

Review Oncology

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives

Fanny Ledys et al.

Summary: Breast cancer remains the leading cause of death in women, and new therapeutic combinations are needed to sensitize breast tumors to anti-PD-(L)1 immunotherapy due to its poor response to immunotherapy.

CANCERS (2021)

Review Biochemistry & Molecular Biology

Immunotherapy in Breast Cancer: When, How, and What Challenges?

Beatriz Henriques et al.

Summary: Breast cancer is the second most common cause of cancer death among women worldwide, and immunotherapy has emerged as a significant treatment strategy, leading to significant advances in treatment. While various immunotherapy approaches have been approved, some patients do not respond to treatment, or experience relapse or progression, mainly due to complex resistance mechanisms.

BIOMEDICINES (2021)

Review Oncology

Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review

Dione Fernandes Tavares et al.

Summary: Breast cancer is a common diagnosis in women, with the subtype triple-negative breast cancer posing a challenge in clinical practice. Immunotherapy is emerging as a new treatment option for breast cancer, although it still faces major challenges.

ONCOLOGY REVIEWS (2021)

Article Oncology

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma

Josep Malvehy et al.

Summary: This study demonstrates that T-VEC induces systemic immune activity and modifies the tumor microenvironment, potentially enhancing the efficacy of combination immunotherapy with other agents.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Biology

CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions

Veethika Pandey et al.

Summary: This study highlights the importance of CXCL10/CXCR3 signaling in the early phase of murine pancreatic cancer, demonstrating its role in mediating chemotaxis, proliferation, and maintenance of inflammatory identity in macrophages within the pancreas. Inhibition of CXCL10/CXCR3 signaling shifts macrophage populations to a tumor-promoting phenotype, increasing fibrosis and lesion progression.
Review Oncology

STING Agonists as Cancer Therapeutics

Afsaneh Amouzegar et al.

Summary: Immunotherapies have significantly impacted cancer treatment, yet some patients do not respond effectively. Recent efforts have been focused on identifying targets that could enhance anti-tumor immune responses, with STING pathway being one novel and promising target. Research on STING agonists has opened avenues for developing more effective strategies in cancer immunotherapy.

CANCERS (2021)

Article Oncology

CXCR6-CXCL16 Axis Promotes Breast Cancer by Inducing Oncogenic Signaling

Hina Mir et al.

Summary: Breast cancer (BrCa) is the second leading cause of cancer-related deaths in American women, and its incidence is increasing. This study highlights the importance of the chemokine axis CXCR6/CXCL16 in promoting BrCa and suggests it as a potential therapeutic target for advanced-stage BrCa.

CANCERS (2021)

Article Oncology

CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer

Yuan-ke Liang et al.

Summary: The study revealed that in breast cancer, the expression of CXCL9 is significantly higher compared to normal tissue and is associated with better survival outcomes in patients with ER-negative tumors. Additionally, CXCL9 is correlated with immune cell infiltration and immune-related biomarkers including CTL4, GZMB, LAG3, PDCD1, and HAVCR2.

FRONTIERS IN ONCOLOGY (2021)

Article Medicine, General & Internal

Photodynamic Therapy in Primary Breast Cancer

Shramana M. Banerjee et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Article Oncology

Photothermal therapies to improve immune checkpoint blockade for cancer

Preethi B. Balakrishnan et al.

INTERNATIONAL JOURNAL OF HYPERTHERMIA (2020)

Article Biochemistry & Molecular Biology

Comprehensive Integration of Single-Cell Data

Tim Stuart et al.

Article Biotechnology & Applied Microbiology

Dimensionality reduction for visualizing single-cell data using UMAP

Etienne Becht et al.

NATURE BIOTECHNOLOGY (2019)

Review Oncology

Electrochemotherapy as a New Modality in Interventional Oncology: A Review

Ute Probst et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)

Article Oncology

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells

Jan Willem Kleinovink et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Article Oncology

In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior

Takuya Osada et al.

CLINICAL CANCER RESEARCH (2017)

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

Review Oncology

Photodynamic therapy and anti-tumour immunity

Ana P. Castano et al.

NATURE REVIEWS CANCER (2006)